Ofatumumab Shows Strong Relapse Control in Chinese Multiple Sclerosis Patients Over 12 Months
A 12-month open-label study of 99 Chinese adults with relapsing multiple sclerosis found that subcutaneous ofatumumab produced an adjusted annualized ...
A 12-month open-label study of 99 Chinese adults with relapsing multiple sclerosis found that subcutaneous ofatumumab produced an adjusted annualized ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.